Filing Details

Accession Number:
0001570562-21-000163
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-19 19:01:00
Reporting Period:
2021-08-17
Accepted Time:
2021-08-19 19:01:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1570562 Evolus Inc. EOLS Pharmaceutical Preparations (2834) 461385614
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1730123 Vikram Malik 520 Newport Center Dr.
Suite 1200
Newport Beach CA 92660
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-08-17 42,083 $10.06 1,256,618 No 4 S Indirect See footnote
Common Stock Disposition 2021-08-18 25,000 $10.44 1,231,618 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Footnotes
  1. The shares were sold by Strathspey Crown Holdings Group, LLC ("SCH") in multiple trades at prices ranging from $9.90 to $10.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. The reported securities are directly owned by SCH and may be deemed beneficially owned by the Reporting Person as a Managing Partner of SCH. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
  3. The shares were sold by SCH in multiple trades at prices ranging from $9.92 to $10.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.